- Vaccine Name: KINRIX
- Target Pathogen: Bordetella pertussis
- Target Disease: Whooping Cough
- Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- Tradename: KINRIX
- Manufacturer: GlaxoSmithKline
- Vaccine Ontology ID: VO_0000067
- Type: Toxoid vaccine + Subunit vaccine + Inactivated or "killed" vaccine
- Status: Licensed
- Location Licensed: USA
- Host Species for Licensed Use: Human
- Allergen: Latex, Neomycin, Polymyxin B.
- Preparation: The diphtheria toxin is produced by growing Corynebacterium diphtheriae in Fenton medium containing a bovine extract. After, they are detoxified with formaldehyde, concentrated by ultrafiltration, and purified by precipitation, dialysis, and sterile filtration.
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Store refrigerated between 2° and 8°C (36° and 46°F), do not freeze.
- Approved Age for Licensed Use: 4 to 6 years of age.
- Contraindication: A severe allergic reaction (e.g., anaphylaxis) after a previous dose of any diphtheria toxoid, tetanus toxoid, pertussis or poliovirus-containing vaccine, or to any component of KINRIX, including neomycin and polymyxin B, encephalopathy within 7 days of administration of a previous pertussis-containing vaccine and progressive neurologic disorders.
- Description: A single dose of KINRIX is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age whose previous DTaP vaccine doses have been with INFANRIX and/or PEDIARIX for the first three doses and INFANRIX for the fourth dose. (FDA: KINRIX)
|
